Qfitlia (Fitusiran)

Fitusiran is a medicine that helps prevent bleeding in people with hemophilia A or B. It is given as a shot under the skin once every month or two. It works by lowering a natural protein that slows clotting, so the blood can clot better.

Brand names:Qfitlia
Medication

What people taking Qfitlia (Fitusiran) report

Every report comes from a Lived member, sent anonymously.

Have you tried Qfitlia (Fitusiran) for Hemophilia A?

NameHow it went

About Qfitlia (Fitusiran)

What It's For

Fitusiran, sold as Qfitlia, is a prescription medicine for hemophilia A and hemophilia B, inherited bleeding disorders in which the blood lacks enough of one clotting protein (factor VIII, or 8, in hemophilia A; factor IX, or 9, in hemophilia B). It is used as routine prophylaxis, meaning regular preventive treatment that lowers how often bleeds happen, in adults and children 12 and older. It is approved for people who have inhibitors and for people who do not. Inhibitors are antibodies some people develop against replacement factor, which make standard factor treatment work poorly. Because fitusiran does not work by replacing factor, it can be used either way. It does not treat a bleed that is already happening, and it is not approved for children under 12.

How It Works

Clotting depends on a balance between proteins that build a clot and proteins that hold clotting in check. In hemophilia, the missing factor tips that balance toward bleeding. Antithrombin is one of the body's main natural brakes on clotting: it switches off thrombin, the enzyme at the center of clot formation. Fitusiran is a small interfering RNA (siRNA), a type of medicine that silences the instructions for one specific protein. After injection it travels mainly to the liver, where it breaks down the genetic message used to make antithrombin. With less antithrombin in the blood, the body generates more thrombin, which helps blood clot despite the missing factor. Because the effect comes from making less of a protein rather than from the drug circulating in the blood, it builds up over weeks to months and also fades slowly after the last dose.

Dosage & Administration

Fitusiran is injected under the skin of the thigh or belly, or the outer upper arm when a caregiver gives it. After training, people can inject it themselves or a caregiver can; for teenagers 12 to 17, an adult should give or supervise the injection. It comes as a 50 mg prefilled pen and a 20 mg vial used for lower doses. Treatment usually starts at 50 mg once every two months. The dose is then tuned with a blood test of antithrombin activity, reported as a percentage of normal. The goal is to keep it between 15% and 35%: low enough to protect against bleeding, but not below 15%, where the risk of blood clots rises. Depending on results, the dose may move up to monthly or down to a smaller amount. Fitusiran is not started if antithrombin is already below 60%. Anyone on regular factor or bypassing-agent prophylaxis (bypassing agents are clotting products used when inhibitors are present) must stop it no later than 7 days after the first fitusiran dose. Bleeds can still happen. From the second week on, they are treated with lower and less frequent doses of factor or bypassing agent than before, because the two together raise clotting more than either alone. This bleed plan should be agreed with the hemophilia team before starting. A missed dose should be given as soon as possible, and the usual schedule then continues from that dose.

Side Effects

The most common side effects in studies were colds and other viral infections, bacterial infections, joint pain, headache, cough and reactions where the shot was given, such as bruising, redness or pain. Raised liver enzymes on blood tests affected about 8 in 100 people, usually without symptoms, which is why liver tests are scheduled. Gallbladder problems, including gallstones and gallbladder inflammation, have occurred and occasionally needed surgery to remove the gallbladder. Call the care team right away about new pain in the stomach or upper abdomen, indigestion, nausea or vomiting. Blood clots are the most serious risk. Get emergency medical help right away for swelling, pain or redness in an arm or leg; severe chest pain or tightness, shortness of breath, coughing up blood or a racing heartbeat; fainting; a severe or lasting headache, confusion, trouble speaking or understanding, or numbness or weakness in the face, arm or leg; or sudden vision changes, eye pain or eye swelling. These signs matter during treatment and after stopping.

Interactions & Warnings

Fitusiran carries a boxed warning, the most prominent warning the US Food and Drug Administration requires, for blood clots and for gallbladder disease. Clots, including a fatal clot in the veins of the brain, occurred mostly with a higher fixed monthly dose that is not approved. On the approved antithrombin-guided dosing, about 1 in 70 people in studies had a clot. Risk is higher when antithrombin stays below 15%, with a central venous catheter (a long-term IV line), after surgery if the bleed-management plan is not followed, with other conditions that raise clot risk, and when bleeds are treated with more factor or bypassing agent than the plan calls for. People with past clots or an inherited clotting tendency were generally left out of the studies. Hormonal birth control may add to clot risk, and the label advises switching to a non-hormonal method before starting. People who have had gallbladder disease with symptoms may be better served by a different hemophilia treatment. Fitusiran should be avoided by people with existing liver disease that impairs liver function. Surgery has been done without stopping fitusiran, but the surgical team needs to know about it and follow bleed-management guidance, since clots after surgery are a recognized risk. There are no data on use during pregnancy or breastfeeding, and the studies included only males, so women and girls with hemophilia should weigh this with their team.

What to Expect

The effect builds gradually, and the first 6 months involve the most testing. Antithrombin is checked before starting, at about months 1, 3, 5 and 6, and after any dose change; liver blood tests are done monthly for at least 6 months and again for 6 months after a dose increase. Once the right dose is found, antithrombin is usually checked once a year. In the main study, about two thirds of people settled on a schedule of one injection every two months. In studies, people on fitusiran had roughly 70% fewer treated bleeds per year, including fewer joint bleeds, than people who treated bleeds only as they happened, with similar results with or without inhibitors. The approved dosing was compared with control groups from earlier trials rather than tested head to head, and it has not been directly compared with regular factor prophylaxis or other preventive medicines. About 15 in 100 people in the main study had to stop because their antithrombin repeatedly dropped below 15%. Stopping should be planned with the care team, because protection against bleeding fades once doses are missed. After the last dose, antithrombin takes about 6 months to return close to normal, so the reduced-dose plan for treating bleeds still applies during that time unless the team advises otherwise.

Questions to Ask Your Doctor

  1. 1.How does fitusiran compare with my current prophylaxis, including factor and other non-factor medicines, for my type of hemophilia?
  2. 2.What exactly is my plan for treating a breakthrough bleed, and what doses of factor or bypassing agent should I use?
  3. 3.How often will my antithrombin and liver tests be done, and what happens if my level falls below 15%?
  4. 4.Do I have anything that raises my risk of clots or gallbladder problems, such as a central line, past clots, gallstones or hormonal birth control?
  5. 5.What should happen before a planned surgery, and what would stopping fitusiran involve?

Last reviewed • Oct 2026

Educational content, not medical advice.